

1 **Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the**
2 **Central African Republic**

3
4 **Viral hepatitis and HIV co-infection in the Central African Republic**

5
6 Parvine Basimane-Bisimwa^{1,2,3,4¶}, Giscard Wilfried Koyaweda[¶], Edgarthe Ngaïganam[¶], Ulrich
7 Vickos⁵, Ornella Anne Demi Sibiro¹, Brice Martial Yambiyo⁶, Benjamin Seydou Sombié⁷, Pulchérie
8 Pélembi⁸, Sandrine Moussa⁸, Claudine Bekondi⁹, Tamara Giles-Vernick¹⁰, Alexandre Manirakiza⁶,
9 Muriel Vray¹¹, Narcisse Patrice Joseph Komas^{1*}

10
11 ¹Viral hepatitis laboratory, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African Republic

12 ²Université Evangélique en Afrique (UEA), Bukavu, Democratic Republic of Congo.

13 ³International Center Advanced for Research and Training (ICART), Bukavu, Democratic Republic of
14 Congo.

15 ⁴Hôpital Général de Référence de Panzi, Bukavu, Democratic Republic of Congo.

16 ⁵Laboratory of arbovirus, haemorrhagic fevers, emerging virus and zoonosis, Institut Pasteur de
17 Bangui, PO Box 923, Bangui, Central African Republic

18 ⁶Epidemiology service, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African Republic

19 ⁷Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso

20 ⁸Service des Retrovirus-VIH, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African
21 Republic.

22 ⁹Centre de Ressources Biologiques, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African
23 Republic

24 ¹⁰Anthropology & Ecology of Disease Emergence Unit, Institut Pasteur, Paris

25 ¹¹Unit of epidemiology of emergent infections, Institut Pasteur, INSERM, Paris.

26 *Corresponding author: nphokas@yahoo.fr / narcisse.komas@pasteur-bangui.fr (NPK) ORCID
new research that has not been certified by peer review and should not be used to guide clinical practice.

27

28 ¶These authors contributed equally to this work

30 **Abstract**

31 **Background:** The Central African Republic (CAR) is one of the countries with the highest prevalence
32 of viral hepatitis infection in the world. The present study describes the geographic distribution of viral
33 hepatitis infections and molecular characterization of these viruses in the CAR.

34 **Methodology:** Out of 12,599 persons enrolled during the 4th Multiple Indicator Cluster Survey of
35 2010 in the CAR, 10,621 Dried Blood Spot (DBS) samples were obtained and stored at -20°C. Of
36 these DBS, 4,317 samples were randomly selected to represent all regions of the CAR. Serological
37 tests for hepatitis B, D, and C viruses were performed using the ELISA technique. Molecular
38 characterization was performed to identify strains.

39 **Results:** Of the 4,317 samples included, 53.2% were males and 46.8% females. The HBsAg
40 prevalence among participants was 12.9% and that HBc-Ab was 19.7%. The overall prevalence of the
41 HCV was 0.6%. Co-infection of HIV/HBV was 1.41% and that of HBV/HDV was 16.6%. A total of
42 77 HBV, 6 HIV, and 6 HDV isolates were successfully sequenced, with 72 HBV (93.5%) strains
43 belonging to genotype E and 5 (6.5%) isolates belonging to genotype D. The 6 HDV isolates all
44 belonged to clade 1, while 4 recombinants sub-type were identified among the 6 isolates of HIV.

45 **Conclusion:** Our study found a high prevalence of HBV, HBV/HDV and HBV/HIV co-infection, but
46 a low prevalence of HCV. CAR is still in an area of high HBV endemicity. This study's data and
47 analyses would be useful for establishing an integrated viral hepatitis and HIV surveillance program in
48 the CAR.

49

50 **Keywords:** HBV; HCV; HBV-HDV co-infection; HIV-HBV coinfections; Prevalence; HBV/HDV
51 Molecular characterization; Hepatitis B virus; Hepatitis C virus; Hepatitis D virus; CAR.

52 **Introduction**

53 Hepatitis is defined as an inflammation of the liver. It can be self-limiting or in some cases,
54 progress to fibrosis (scarring), cirrhosis, or liver cancer. Hepatitis may be caused by toxins, certain
55 drugs, heavy alcohol use, and bacterial and viral infections. Hepatitis viruses are the most common
56 cause of hepatitis in the world [1].

57 There are 5 main hepatitis viruses, referred to as types A, B, C, D, and E. Each type of hepatitis is
58 caused by a different virus, is spread differently, and accounts for variable prevalence and mortality
59 around the world [1]. Globally, viral hepatitis infection is a major public health problem. Each year,
60 1.4 million people die from viral hepatitis-related cirrhosis and liver cancer [2]. Prevalence varies
61 according to geographical area. Following Asia, Africa has the second largest number of chronic
62 HBV carriers and is considered to be a region of high endemicity [3]. In 2015, the number of deaths
63 caused by hepatitis viruses resembled the number of deaths caused by tuberculosis and higher than
64 those caused by HIV [4]. Viral hepatitis mortality has been increasing over time, whereas
65 tuberculosis and HIV mortality has declined. In most cases, mortality due to viral hepatitis in 2015
66 was caused by chronic liver disease and primary liver cancer, causing some 720,000 and 470,000
67 deaths respectively [4]. The HCV epidemic affects all regions of the world, with major differences
68 between and within countries [4]. The HDV, a satellite RNA-virus depending on HBV for its
69 propagation. Both HBV and HDV occur worldwide, with an estimated 240 million people
70 worldwide chronically infected with HBV [4,5], of whom approximately 15 to 20 million, or 5%
71 are co-infected with HDV [6]. In combination with HBV, HDV causes the most severe form of
72 viral hepatitis in humans, including fulminant hepatitis and hepatocellular failure, with rapid
73 progression to hepatic cirrhosis followed by hepatic decompensation, and an increased risk of
74 hepatocellular carcinoma [7–9]. Additionally, HBV/HIV coinfection increases the morbidity and
75 mortality beyond the cause of mono-infection by either one of those viruses. HBV patients
76 coinfecting with HIV have higher levels of hepatitis B viremia, have progression to chronic hepatitis

77 B that is approximately five times as fast as that among people infected with only HBV, and have a
78 higher risk of cirrhosis and hepatocellular carcinoma[10].
79 Although Africa has very high HBV endemicity, HDV prevalence remains poorly known and is thus
80 increasingly studied [4]. Nevertheless, in Africa, of the estimated 65 million chronic HBV carriers,
81 about one-fourth of HBsAg-positive individuals show dual-infection with HDV. Thus, Central Africa
82 has an overall prevalence of 25.6%, West Africa 7.3%, and East and South Africa 0.05% [11].
83 Numerous seroprevalence studies of viral hepatitis have been conducted in CAR between 1984 and the
84 present day, most focusing on the capital Bangui and its suburbs [12,13]. Although national studies to
85 evaluate national prevalence of HIV (3.5%) [14] and HIV/HBV coinfection have been conducted, in
86 addition to Bangui-centered studies of HBV/HDV [11,15], no studies to date have estimated CAR's
87 HBV/HDV national prevalence. This study therefore sought describe the national geographic
88 distribution of viral hepatitis infections and of HBV/HIV and HBV/HDV co-infections , and to
89 produce a molecular characterization of these viruses among CAR's general population.

90

91 ***Methodology***

92 ***Study strategy and sample size***

93 This is a non-interventional descriptive (retrospective) study based on Dried Blood Spot (DBS)
94 samples obtained as part of the 4th Multiple Indicator Cluster Survey (MICS4) in the Central African
95 Republic (CAR) in 2010, carried out as part of the United Nations Children's Fund (UNICEF)
96 program to estimate the prevalence of HIV infection in the country's general population. Out of the
97 12,599 persons enrolled during this MICS4, 10,621 DBS samples were obtained and stored at -20°C.
98 The sample size for our study was calculated based on the previously reported prevalence of HBsAg
99 (10.6%) [11], a precision of 3% with a 95% confidence interval. From the 10,621 DBS, due to
100 insufficient amounts of some samples, only 9,378 were exploitable, covering all 14 prefectures and
101 Bangui, CAR's capital city. Samples from two prefectures (Nana-Gribizi and Ouham-Pende) were lost
102 during the storage of DBS. Of the 9,378 exploitable DBS, 413 tested HIV-positive, with 8,965 HIV-

103 negative. Among the 8,965 HIV-negative samples, a random selection was performed to include 4,467
104 samples in this study, to which we added 413 HIV-positive samples. We used all HIV positive samples
105 to determine HIV/hepatitis co-infection prevalence.

106

107 ***Socio-demographic data***

108 Socio-demographic data were obtained from the Central African Institute of Statistics, Economic and
109 Social Studies (ICASEES), which collected and archived all data related to each sample, including sex,
110 age, ethnicity, educational level, marital status, residential area (region and urban or rural setting). All
111 data were anonymized before processing the analyses. These data were collected from the standard
112 questionnaire of the survey (www.childinfo.org), adapted to the context of Central African Republic.

113

114 ***Serological tests***

115 Serological tests for hepatitis B, D and C viruses were carried out using the ELISA (enzyme-linked
116 immunosorbent assay) technique on Dried Blood Spot (DBS) stored at the Biological Resources
117 Centre at the Institut Pasteur de Bangui. These samples were made available to the team as soon as the
118 ethical approval was obtained in February 2012. The serological tests began on 8 May 2013. The HBV
119 markers HBsAg, anti-HBc (total), and anti-HBc (IgM) were tested using Abbott-Murex version 3
120 (Abbott-Murex Biotech Ltd, Dartford, Kent, UK) for the respective markers. Anti-HDV antibody was
121 tested using the DiaSorin kit for HDV, and Anti-HCV antibody (HCV-Ab) using the Murex anti-HCV
122 kit (DiaSorin, DiaSorin S. P.A. UK Branch Central Road). Serological tests were performed and
123 interpreted according to the manufacturer's recommendations.

124

125 ***Nucleic Acid Extraction and PCR amplification***

126 Viral nucleic acids (DNA/RNA) were extracted with the Qiagen Kits (QIAamp DNA Blood Mini Kit
127 250 and QIAamp Viral RNA Mini Kit 50) according to the manufacturer's procedures. Subsequently,
128 the *PreS1* region of the HBV was amplified using a primer pair P1 (5'-

129 TCACCATATTCTTGGGAACAAGA-3') /P2 (5'-TTCCTGAACTGGGAGCCACCA-3') with an
130 expected PCR product of 479 bp. For HIV, a nested RT-PCR was used to amplify the protease region
131 of the *pol* gene using two pairs of primers: PRIn1 (5'-TTT-TTT-AGG-GAA-AAT-TTG-3') /PRIn2
132 (5'-ATT-TTC-AGG-CCC-AAT-TTT-TGT-3') and PRIn3 (5'-CAG-ACC-AGA-GCC-AAC-AGC-
133 3')/PRIn4 (5'-TCT-TCT-GTC-AAT-GGC-CAT-TGT-3) for primary PCR and nested PCR
134 respectively according to the ANRS protocol (<http://www.hivfrenchresistance.org>). The R0 region of
135 HDV was amplified with the primers Casey sens (5'CATGCCGACCCGAAGAGGAAAG3') and anti-
136 sens (5'GAAGGAAGGCCCTCGAGAACAAGA3'), according to the previously published method
137 [16].

138

139 *Sequencing*

140 The PCR products were first purified using the Qiagen kit (QIAquick PCR Purification kit,
141 www.qiagen.com/handbooks), then sent to GATC (Germany) for sequencing using the Sanger
142 method.

143

144 *Sequences analysis*

145 The chromatograms of the sequences obtained were cleaned and analyzed in CLC genomic workbench
146 V.8. The HIV subtypes were determined online, using the Stanford University website (HIV DRUG
147 RESISTANCE DATABASE, <http://www.sierra2.stanford.edu>). For HBV and HCV, the sequences
148 were aligned and compared with the reference sequences downloaded from the database (Genbank),
149 and construction of the phylogenetic trees was carried out using MEGA X software.

150 All sequences obtained were submitted to NCBI and were given the following accession number: **HBV**
151 (*MT155997- MT156072*), **HDV** (*MT028414- MT028419*), and **HIV** (*MT121102- MT121107*).

152

153 *Statistical analysis*

154 Data were analyzed using STATA Software.14. Percentages with a 95% confidence interval (CI) were
155 calculated. HBV-positive and HBV-negative groups were compared using χ^2 test or Fisher's exact test
156 for dichotomous variables and Student's t-test or Wilcoxon rank-sum test for continuous variables.
157 All variables associated with HBV in univariate analysis ($p < 0.25$) were then included in a backward
158 stepwise logistic regression. A p -value ≤ 0.05 was considered statistically significant.

159

160 *Ethical considerations*

161

162 Because this study was based partly on retrospective data linked to the fourth Multiple Indicator
163 Cluster Survey (MICS-4) carried out in 2010, which was coupled with HIV screening in the general
164 population, the introduction of a new consent form for participants was neither necessary,
165 recommended or indeed possible.

166 The protocol anonymised the socio-demographic data stored at the « Institut Centrafricain des
167 Statistiques, des Études Économiques et Sociales (ICASEES) » and participants' blood samples, dried
168 blood spot (DBS), stored at the Biological Resource Centre of the Institut Pasteur de Bangui. The
169 detection of HIV infection during this survey is based on the anonymous-linked protocol developed by
170 the international DHS (Demographic and Health Surveys) programme and approved by the ICF Macro
171 Ethics Committee. According to this protocol, no name or other individual or geographical
172 characteristic that could identify an individual was linked to a blood sample. The standard MICS-4
173 questionnaire used (www.childinfo.org) was adapted to the context of the Central African Republic.
174 The “Comité Scientifique chargé de Validation des Protocoles et des Résultats de Recherche en Santé
175 (CSVPRS)” of the Faculty of Health Sciences of the University of Bangui (Central African Republic),
176 which acts as the Central African Republic's national ethics committee, also approved the specific
177 anonymous-linked protocol for the MICS-4 survey under number 2/UB/FACSS/CSVPRS/10. The tests
178 used to detect HIV infection were strictly anonymous, and it was not possible to inform those tested of
179 the results of their examination. However, at the time of the MICS-4, whether or not they had agreed
180 to be tested for HIV, eligible persons (those providing their consent to be included in the survey)

181 received a coupon to obtain, if they so wished, advice and a free HIV test at a “Centre de Prévention et
182 de Dépistage Volontaire (CPDV)”.

183 The protocol for this study was also assessed by the CSVPRS, which issued a favorable ethical
184 approval under number 6/UB/FACSS/CSVPRS/12. In the protocol submitted to the CSVPRS, we
185 noted the impossibility of collecting informed consent from participants due to the retrospective nature
186 of the study, which used DBS samples stored at the Biological Resources Centre of the Institut Pasteur
187 de Bangui, and the sociodemographic data being anonymous at the outset. We explained that there was
188 no possibility of contacting participants in order to obtain their consent again. The socio-demographic
189 data used to analyse the results of the study were obtained from the ICASEES, which collected and
190 archived all these data in relation to each DBS sample. An anonymous number was used to link the
191 biological results to the individual data, but conserved anonymity, again making it impossible to
192 contact participants to obtain their consent.

193

194 ***Results***

195

196 ***Population characteristics***

197 Among the 4,317 samples analyzed, 2,297 were from males (53.2%) and 2020 from females (46.8%)
198 with a sex ratio of 1.13. The majority of subjects had either primary school or no education (44.8% and
199 33.4% respectively). More than half of the participants (2356/4317 or 54.6%) identified themselves as
200 of the Protestant religion. The economic quintiles were second (25.0%), poor (22.7%) and medium
201 (22.7%).

202 ***Prevalence of HBV, HCV, HBV/HIV, and HBV/HDV co-infections***

203 Positive HBsAg and HBc-Ab were found in 555 subjects (12.9%), and 849 (19.7%), respectively. The
204 overall prevalence of anti-HCV was 0.65%. Co-infection of HBV/HIV was found in 49 subjects
205 (1.4%) of 3477 HBV tested population, and HBV/HDV co-infection was found in 92 subjects (16.6%)

206 of the HBV infected population. The prevalence of different hepatitis viral markers and HBV/HIV and
207 HBV/HDV associated with socio-demographic data are reported in *Table 1*.

208 **Table 1.** Prevalence and distribution of HBsAg, HBc Ab, HCV, HBsAg/HIV and, HBsAg/HDV coinfections

209

210

Characteristics	Number	Percentage	Coinfection HIV/HBsAg			HBsAg			HBc antibody			HCV antibody			HDV* antibody		
			Positive (n)	%	<i>P</i>	Positive (n)	%	<i>P</i>	Positive (n)	%	<i>P</i>	Positive (n)	%	<i>P</i>	Positive (n)	%	<i>P</i>
Gobal prevalence	4317	100	49(3477)	1.4		555(4317)	12.9		849(4317)	19.7		28(4317)	0.6		92(555)	16.6	
Sex																	
Male	2297	53.2	32(1858)	1.7	0.107	280	12.2	0.163	443	20.1	0.503	14(2297)	0.6	0.733	53(280)	18.9	0.133
Female	2020	46.8	17(1589)	1.1		275	13.6		406	19.3		14(2020)	0.7		39(275)	14.2	
Age (years)																	
0 to 25	1075	24.9	13(846)	1.5		147(1075)	13.8		226(1075)	21.0		3(1075)	0.3		24(147)	16.3	
26 to 35	1236	28.6	10(986)	1.0	0.454	161(1236)	13.0	0.696	254(1236)	20.6	0.271	7(1236)	0.6	0.012	24(161)	14.9	0.525
36 to 45	961	22.3	10(766)	1.3		122(961)	12.7		177(961)	18.4		4(961)	0.4		18(122)	14.7	
> 45	1045	24.2	16(849)	1.9		125(1045)	12.0		192(1045)	18.4		14(1045)	1.3		26(125)	20.8	
School level																	
No school	1442	33.4	13(1150)	1.1		184(1442)	12.8		282(1442)	19.6		14(1442)	1.0		32(184)	17.4	
Preschool	2	0.1	0(1)	0.0		0(2)	0.0		0(2)	0.0		0(2)	0.0		0(0)	0.0	
Primary	1934	44.8	20(1554)	20.0	0.194	259(1934)	13.4	0.822	396(1934)	20.5	0.629	12(1934)	0.6	0.268	47(259)	2.4	0.456
Secondary and High	848	19.6	13(670)	1.9		101(848)	11.9		155(848)	18.3		2(848)	0.2		12(101)	11.8	
University	91	2.1	3(72)	4.8		11(91)	12.1		16(91)	17.6		0(91)	0.0		1(11)	9.1	
**Economic quintile																	
Poor	979	22.7	10(786)	1.3	0.001	141(979)	14.4	0.155	217(979)	22.2	0.033	8(979)	0.8	0.840	25(141)	17.7	0.438

Second	1079	25.0	9(874)	1.0	134(1079)	12.4	221(1079)	20.5	6(1079)	0.6	20(134)	41.9			
Medium	978	22.6	7(785)	0.9	119(978)	12.2	187(978)	19.1	7(978)	0.7	19(119)	16.0			
Fourth	745	17.3	8(595)	1.3	82(745)	11.0	120(745)	16.1	3(745)	0.4	10(82)	12.2			
Richer	536	12.4	15(407)	3.7	79(536)	14.7	104(536)	19.4	4(536)	0.7	18(79)	22.8			
Religion															
Animist, Buddhist, other	69	1.60	2(55)	3.6	10(69)	14.5	15(69)	21.7	0(69)	0.0	2(10)	20.0			
Catholic	1344	31.1	8(1081)	0.7	164(1344)	12.2	256(1344)	19.0	9(1344)	0.7	30(164)	18.3			
Muslim	514	11.9	10(402)	2.5	74(514)	14.4	117(514)	22.8	0.290	2(514)	0.4	0.842	18(74)	24.3	0.195
Atheist	34	0.8	0(27)	0.0	4(34)	11.7	9(34)	26.5	0(34)	0.0	0(4)	0.0			
Protestant	2356	54.6	29(1882)	1.5	303(2356)	12.9	452(2356)	19.2	17(2356)	0.7	42(303)	13.9			

(*) : Analysis of HDV in 555 positive AgHBs

(**) : The Economic quintile is the economic world bank classification.

217

218 No difference of HBV infection was observed between age groups ($p=0.70$), but for HCV infection, a
219 significant difference was observed for subjects older than 45 years ($p=0.012$). Among districts the
220 prevalence of the four viruses varied (*Table 2*). Even among districts with the lowest blood samples
221 collection,, Vakaga reported the highest prevalence of HBsAg (33.3%), followed by Bamingui-
222 Bangoran (19.5%) and Ouaka (16.9%). However, in Lobaye and Mambere-Kadéi, HBV prevalence
223 was 8.9% and 8.1% respectively. The global prevalence of HBV/HIV co-infection was 1.41%, with
224 the highest prevalence among Bangui samples (5.1%), followed by Haut-Mbomou (3.7%) and Haute-
225 Kotto (3.4%).

226 For ethnic groups, prevalence of HBsAg (41.7%; $p< 0.001$) and of anti-HBc antibody (57.1%; $p<$
227 0.001) was higher among “non identified ethnic groups”, followed by the Banda ethnic group (15.1%
228 and 24.2%), respectively). In contrast, prevalence of HBV/HIV co-infection was slightly higher in the
229 Hausa ethnic group, followed by the Zande/Nzakara ethnic group. Analyses of factors associated with
230 each infection are shown *in Table 3*.

231

Table 2. Geographical distribution of hepatitis (B, C and D) viruses

Geographical distribution	Number	Percentage	Coinfection HIV/HBsAg			HBsAg			HBc Antibody			HCV Antibody			HDV Antibody*		
			Positive (n)	%	P	Positive (n)	%	P	Positive (n)	%	P	Positive (n)	%	P	Positive (n)	%	P
Residence/Prefecture																	
Rural	2704	62.6	20(2192)	0.9	0.001	365(2704)	13.5	0.103	610(2704)	22.6	0.001	13(2704)	0.5	0.075	58(365)	15.9	0.547
Urban	1613	37.4	29(1255)	2.3		190(1613)	11.8		239(1613)	14.8		15(1613)	0.9		34(190)	17.9	
Prefecture																	
Bamingui Bangoran	246	5.7	1(189)	0.5		48(246)	19.5		103(246)	41.9		5(246)	2.0		10(48)	20.8	
Bangui (City of) **	341	7.9	13(254)	5.1		51(341)	15.0		74(341)	21.7		2(341)	0.6		8(51)	15.7	
Basse Kotto	287	6.6	1(247)	0.4		31(287)	10.8		55(287)	19.2		6(287)	2.1		3(31)	9.7	
Haut Mbomou	259	6.0	7(191)	3.7		39(259)	15.1		49(259)	18.9		1(259)	0.4		5(39)	12.8	
Haute Kotto	277	6.4	7(208)	3.4		39(277)	14.1		49(277)	17.7		1(277)	0.4		5(39)	12.8	
Kemo	379	8.8	3(307)	1.0		59(379)	15.6		74(379)	19.5		3(379)	0.8		11(59)	18.6	
Lobaye	281	6.5	0(245)	0.0	0.001	25(281)	8.9	0.001	28(281)	10.0	0.001	2(281)	0.7	0.031	7(25)	28.0	0.150
Mambere Kadei	335	7.8	0(271)	0.0		27(335)	8.1		73(335)	21.8		0(335)	0.0		9(27)	33.3	
Mbomou	307	7.1	4(246)	1.6		42(307)	13.7		50(307)	16.3		0(307)	0.0		4(42)	9.5	
Nana Mambere	335	7.8	2(259)	0.8		37(335)	11.0		39(335)	11.6		1(335)	0.3		4(37)	10.8	
Ombella Mpoko	348	8.1	2(271)	0.7		35(348)	10.1		77(348)	22.1		0(348)	0.0		5(35)	14.3	
Ouaka	279	6.5	3(219)	1.4		47(279)	16.8		92(279)	33.0		2(279)	0.7		7(47)	14.9	
Ouham	291	6.7	2(256)	0.8		32(291)	11.0		39(291)	13.4		3(291)	1.0		4(32)	12.5	

Sangha Mbaere	325	7.5	4(266)	1.5	34(325)	10.5	34(325)	10.5	2(325)	0.6	10(34)	29.4
Vakaga	27	0.6	0(18)	0.0	9(27)	33.3	13(27)	48.1	0(27)	0.0	0(9)	0.0
Ethnicity												
NIEG(1)	348	8.1	4(262)	1.6	51(348)	41.1	82(348)	57.0	4(348)	1.2	11(51)	25.6
Banda	1183	27.4	12(927)	1.3	179(1183)	15.1	286(1183)	24.2	11(1183)	0.9	31(179)	17.3
Gbaya	1074	24.9	11(880)	1.2	110(1074)	10.2	174(1074)	16.2	6(1074)	0.6	20(110)	18.2
Haoussa	238	5.5	5(188)	2.7	32(238)	13.4	50(238)	21.0	2(238)	0.8	7(32)	21.9
Mandja	364	8.4	4(288)	1.4	54(364)	14.8	75(364)	20.6	1(364)	0.3	4(54)	7.4
Mboum	60	1.4	1(52)	1.9	2(60)	3.3	3(60)	5.0	0(60)	0.0	1(2)	50.0
Ngbaka/Bati	326	7.5	3(274)	1.1	39(326)	12.0	47(326)	14.4	2(326)	0.6	6(39)	15.4
Sara	149	3.4	0(123)	0.0	16(149)	10.7	29(149)	19.5	0(149)	0.0	2(16)	12.5
Yakoma/Sango	257	5.9	3(215)	1.4	22(257)	8.6	39(257)	15.2	2(257)	0.8	4(22)	18.2
Zande/Nzakara	318	7.4	6(238)	2.5	50(318)	1.7	64(318)	20.1	0(318)	0.0	6(50)	12.0

(*) : Analysis of HDV in 555 positive AgHBs

(**) : City of Bangui : Bangui is the capital of Central African Republic

(1) : Non identified ethnic groups

Figure 1: Circulation of viruses and their genotypes in CAR. All four viruses were present in the southeastern part of the Country. Bangui, the capital city, is affected by all three viruses and the circulation of the two genotypes (D and E) of HBV.

241 *Associated risk factors for HIV-HBV co-infection*

242 In our multivariate analysis, being wealthier (OR 4.25, 95% CI: 1.71-10.51) and living in an urban
243 area (OR 2.56, 95% CI: 1.44 - 4.56), more specifically Bangui and Vakaga (OR 10.14, 95%CI 1.31-
244 78.21), were associated with HIV/HBV co-infection (Table 3).

245

246 **Table 3.** Association between HBV/HIV coinfection and risk factors.

247

248

Caractéristiques	Co-infection HIV/HBV		
	OR	<i>p</i>	IC(95%)
**Economic quintile			
Wealthier	4.25	0.002	[1.71 - 10.51]
Residence/Prefecture			
Urban	2.56	0.001	[1.44 - 4.56]
Prefecture			
Bangui (City of) **	10.14	0.026	[1.31 - 18.21]
Vakaga			

249

250

251

252 *Molecular characterization of HBV, HDV, and HIV isolates*

253

254 A total of 77 HBV strains based on the *PreS1* region were sequenced. Of these 77 strains, 6 were
255 HBV/HDV co-infected and 6 strains were HBV/HIV co-infected. Of the 77 HBV isolates, 72
256 strains (93.5%) belonged to genotype E, and 5 isolates (6.5%) to genotype D (*Figure 2*). Of the 92
257 HDV positive samples, 6 samples were successfully sequenced and all belonged to clade 1 (*Figure*
258 3).

259

260 **Figure 2:** Phylogenetic analyses of 77 HBV isolates. The tree was constructed in MEGA using the
261 Neighbor-joining statistical method, the Kimura-2 parameter model, and the bootstrap method of
262 1000 replicates. The black cercles represent reference sequence genotypes A-H downloaded from
263 the database. The remaining are HBV sequences discussed in the present study, and the two
264 genotypes (E and D) are mentioned on the tree.

265
266 **Figure 3:** Phylogenetic analyses of the 6 HDV isolates. The tree was constructed in MEGA using
267 the Neighbor-joining statistical method, the Kimura-2 parameter model, and the bootstrap method
268 of 1000 replicates. The black cercles represent the HDV sequences discus by the present study, and
269 the remaining are the reference sequences with the country's names.

270
271 Table 4 presents the 6 sequences of HIV and their GenBank accession number. After similarity
272 analysis via the NCBI database and the Stanford University website sub-types-1 (A1 and G), 4
273 recombinants of sub-type-1 were identified.

274 **Table 4.** Different subtypes of HIV-1 isolate

<i>Laboratory ID/ GenBank Accession Number</i>	<i>Sub-types</i>	<i>Similarity (%)</i>
<i>CARVIHBG280/ MT121104</i>	CRF01_AE	100
<i>CARVIHVK022/ MT121105</i>	A1	100
<i>CARVIHSM173/ MT121107</i>	G	94.6
<i>CARVIHSM651/ MT121102</i>	CRF02_AG	100
<i>CARVIHKE584/ MT121103</i>	CRF12_BF	100
<i>CAVIHHK175/ MT121106</i>	CRF11_cpx	100

275

276

277

Discussion

278

279 The study reported the prevalence of viral hepatitis B, C and Delta biomarkers and the molecular
280 characterization of HBV, HDV, HCV and HIV/Hepatitis coinfection of DBS from a nationwide
281 investigation in the CAR.

282 In all our analyzed cohorts, HBsAg was highly endemic, but its prevalence varied widely among
283 different regions of the CAR, ranging from 8.1% in Mambere Kadéi to 33.3% in Vakaga. Although
284 it is difficult to compare different age groups, HBsAg prevalence was similar in children and adults:
285 0 to 25 years (13.7%), 25 to 35 years (13.0%), 36 to 45 years (12.7%), and > 45 years (12.0%).
286 These results resemble those of a previous study showing constancy in HBV prevalence among all
287 age groups in the CAR [17]. This finding may indicate a high burden and an excessive risk of early
288 infection with HBV in children, resulting in a high HDV prevalence (16.6%), which has a similar
289 distribution for HBV across all age groups. Previous studies have designated the CAR as an
290 endemic region for HBV and HDV co-infection [11,15,18,19].

291 The seroprevalence of HBV and HIV co-infection was 1.4%, demonstrating that the CAR is an
292 endemic region for this co-infection.

293 In this study, the prevalence of HBe antibody was 19.7%. The distribution of this prevalence
294 follows HBsAg prevalence. The presence of these antibodies indicates that a high proportion of the
295 population had been exposed to HBV. That prevalence is high in rural areas (22.6%; $p=0.001$),
296 among the economically poor (22.7%), in the Vakaga and Bamingui Bangoran regions (48.11 %
297 and 41.9% respectively; $p<0.001$), and among other ethnic groups as well as the Banda group (57.1
298 and 24.2%; $p<0.001$). Compared to previous studies in CAR, this prevalence has significantly
299 decreased, halving since 2010 when it was 42.3% [31], declining to 27.1% in rural communities in
300 2013 [11], and to 26.7% among students and 21.4% among pregnant women in 2018 [15]. This
301 reduction may be explained by the intensification of hepatitis B surveillance measures in blood
302 transfusion and the introduction of hepatitis B vaccination in the Expanded Program of
303 Immunisation in CAR in 2008.

304 Although HCV treatment has not been yet initiated in CAR, HCV prevalence in this study was very
305 low (0.65%). Our finding contrasts with a previous review estimating HCV prevalence in Sub-
306 Saharan Africa between 2000 and 2013, which showed West and Central Africa with the highest
307 HCV prevalence [21]. In our study, HCV prevalence in the Bangui samples was 0.59%. We found a
308 higher prevalence in Bamingui-Bangoran samples (2.03%), with variability across regions and no
309 cases at all among Vakaga samples (Table 2). The Bamingui-Bangoran and Vakaga prefectures are
310 in close proximity, but Vakaga is the most sparsely populated prefecture in the CAR, where very
311 few blood samples were collected compared to other prefectures. We would suggest, then, that
312 socio-demographic and economic factors of these prefectural populations may account for the
313 differential prevalence of these neighboring regions affecting the prevalence of these viruses.

314 In addition, the prevalence of anti-HCV was lower in the 0 to 25 age group and higher in those over
315 45 years old. Similar results have been reported in CAR, Cameroon and Gabon, where massive
316 iatrogenic transmission during medical campaigns through improperly sterilized syringes, needles
317 and the transfusion of contaminated blood products may explain the high prevalence among elderly
318 subjects rather than continuous exposure [32, 33].

319 The main risk factors of HBV identified in our study were economic quintile, religion, residence,
320 prefecture, and ethnicity.

321 From this study, 77 isolates of HBV were sequenced and genotyped. HBV was categorized into
322 eight genotypes from A to H, based on a divergence of more than 8% in the entire nucleotide
323 sequence of the viral DNA. Two additional genotypes I and J were recently proposed [22]. In the
324 CAR, however, evidence of only three of these HBV genotypes (A, D and E) were reported in
325 previous studies [15,18,23,24].

326 The present study identified two HBV genotypes (D and E), with HBV genotype E accounting for
327 the dominant strains circulating throughout the CAR (figure 1). This finding conforms with
328 previous studies identifying HBV genotypes E as the most dominant strains circulating in West and
329 Central Africa [18,25]. This HBV genotype has very low diversity and emerged recently, just 200

330 years or less [25]. HBV genotype D has already been previously described in a Bangui patient with
331 chronic hepatitis [18]. This genotype is predominant in the Maghreb [26], and its low representation
332 in CAR suggests that it may be imported by population and trade movements with other countries in
333 North, West, and Central Africa.

334 HDV clades (1 to 8) varied across geographic regions [27]. From the present study, all 6 isolates
335 belong to clade 1, in accordance with a previous study [28]. The HDV clade 1 has been reported to
336 have rapid and aggressive HDV virion formation and dissemination, making patients infected with
337 this type suffering more adverse outcomes and decreased chances of survival. This finding requires
338 further study of liver disease patients in the CAR.

339 Among the 6 isolates of HIV co-infected with HBV in this study, circulating recombinant forms
340 CRF (CRF01_AE, CRF02_AG, CRF12_BF) and the CRF11_cpx complex were identified. These
341 isolates have already been described as part of the pandemic subtypes in Africa [28,29]. In the
342 CAR, the CRF11_cpx complex has been described as predominant. It is associated with
343 antiretroviral resistance, followed by the A1 type [30].

344 Our study has certain limitations that should be considered, notably the absence of co-infection
345 HIV/HCV, triple infection HB/HCV/HDV or HIV/HBV/HCV, and multiple infection
346 HIV/HBV/HCV/HDV, as well as the absence of detection of HCV-RNA sequences. Additionally,
347 the study did not include an assessment of liver function.

348

349 **Conclusion**

350 This study provides a national prevalence and geographical distribution of hepatitis viruses in the
351 CAR, and it shows that hepatitis viral infections remain a serious public health problem in the
352 country. HBV and HDV remain highly prevalent. HBV prevalence was distributed equally across
353 age groups, and genotype E remains dominant. Our results assume? Suggest? that high prevalence
354 of HBV and HBV/HDV co-infection continue to be responsible for morbidity and mortality, despite
355 the introduction of HBV vaccination in 2008. The data and analysis from this study will be useful in

356 assisting authorities to implement measures to limit HBV, HDV, HCV, and HIV infections and
357 coinfection in the CAR.

358

359 **Acknowledgment:** We thank the «Institut Centrafricain des Statistiques et des Etudes
360 Economiques et Sociales – ICASEES for providing us with the statistical data for this study.

361

362 **Funding:** No fundings

363

364 **Competing interest:** The authors declare that they have no competing interest

365

366 **Authors' contributions**

367 **Conceptualization:** Narcisse Patrice Joseph Komas, Muriel Vray, Alexandre Manirakiza, Sandrine
368 Moussa, Claudine Bekondi

369 **Data curation:** Narcisse Patrice Joseph Komas, Parvine Basimane-Bisimwa, Brice Martial
370 Yambiyo, Alexandre Manirakiza

371 **Formal analysis:** Parvine Basimane-Bisimwa, Giscard Koyaweda, Brice Martial Yambiyo,
372 Alexandre Manirakiza, Benjamin Seydou Sombié, Ulrich Vickos, Narcisse Patrice Joseph Komas

373 **Investigation:** Parvine Basimane-Bisimwa, Giscard Koyaweda, Edgarthe Ngaïganam, Ornella
374 Anne Demi Sibiro,

375 **Methodology:** Parvine Basimane-Bisimwa, Giscard Koyaweda, Muriel Vray, Narcisse Patrice
376 Joseph Komas

377 **Project Administration :** Narcisse Patrice Joseph Komas,

378 **Resources:** Sandrine Moussa, Pulchérie Pélembi, Narcisse Patrice Joseph Komas

379 **Supervision:** Narcisse Patrice Joseph Komas

380 **Writing – original draft:** Parvine Basimane-Bisimwa, Giscard Koyaweda, Narcisse Patrice Jospheh
381 Komas

382 **Writing – review & editing:** Parvine Basimane-Bisimwa, Giscard Wilfried Koyaweda, Ulrich
383 Vickos, Tamara Giles-Vernick, Alexandre Manirakiza, Muriel Vray, Narcisse Patrice Komas

384

385 **References**

- 386 [1] Valenzuela P. Hepatitis A, B, C, D and E viruses: Structure of their genomes and general
387 properties. *Gastroenterol Jpn* 1990;25:62–71. doi:10.1007/BF02779931.
- 388 [2] Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral
389 hepatitis and preventive strategies. *World J Clin Cases* 2018;6:589–99.
390 doi:10.12998/wjcc.v6.i13.589.
- 391 [3] Papastergiou V, Lombardi R, MacDonald D, Tsochatzis EA. Global epidemiology of
392 hepatitis B virus (HBV) infection. *Curr Hepat Rep* 2015;14:171–8. doi:10.1007/s11901-015-
393 0269-3.
- 394 [4] WHO. World Health Organization. Global Hepatitis Report. 2017a. *Glob Hepat Program*
395 *Dep HIV/AIDS* 2017;Disponível:14.
- 396 [5] Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus
397 infection: New estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine*
398 2012;30:2212–9. doi:10.1016/j.vaccine.2011.12.116.
- 399 [6] Hepatitis D n.d. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-d> (accessed June
400 19, 2020).
- 401 [7] Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it
402 differ from hepatitis B monoinfection? *Saudi J Gastroenterol* 2012;18:18–22.
403 doi:10.4103/1319-3767.91731.
- 404 [8] Puigvehí M, Moctezuma-Velázquez C, Villanueva A, Llovet JM. The oncogenic role of
405 hepatitis delta virus in hepatocellular carcinoma. *JHEP Reports* 2019;1:120–30.
406 doi:<https://doi.org/10.1016/j.jhepr.2019.05.001>.
- 407 [9] Abbas Z, Abbas M, Abbas S, Shazi L. Hepatitis D and hepatocellular carcinoma. *World J*

- 408 Hepatol 2015;7:777–86. doi:10.4254/wjh.v7.i5.777.
- 409 [10] Hoffmann CJ TC. Clinical implications of HIV and hepatitis B co-infection in Asia and
410 Africa. *Lancet Infect Dis* 2007;402–409.jour
- 411 [11] Stockdale AJ, Chaponda M, Beloukas A, Phillips RO, Matthews PC, Papadimitropoulos A,
412 et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review
413 and meta-analysis. *Lancet Glob Heal* 2017;5:e992–1003. doi:10.1016/S2214-
414 109X(17)30298-X.
- 415 [12] Komas NP, Vickos U, Hübschen JM, Béré A, Manirakiza A, Muller CP, et al. Cross-
416 sectional study of hepatitis B virus infection in rural communities, Central African Republic.
417 *BMC Infect Dis* 2013;13:286. doi:10.1186/1471-2334-13-286.
- 418 [13] Crovari P, Santolini M, Bandettini R, Bonanni P, Branca P, Coppola RC. Epidemiology of
419 HBV and HDV infections in a rural area of Central African Republic. *Prog Clin Biol Res*
420 1991;364:69–73.
- 421 [14] Classement des États du monde par prévalence du VIH (% population âgée de 15 à 49 ans)
422 n.d.[https://atlasocio.com/classements/sante/maladies/classement-etats-par-prevalence-vih-](https://atlasocio.com/classements/sante/maladies/classement-etats-par-prevalence-vih-pourcentage-monde.php#google_vignette)
423 [pourcentage-monde.php#google_vignette](https://atlasocio.com/classements/sante/maladies/classement-etats-par-prevalence-vih-pourcentage-monde.php#google_vignette) (accessed January 18, 2021).
- 424 [15] Komas NP, Ghosh S, Abdou-Chekaraou M, Pradat P, Al Hawajri N, Manirakiza A, et al.
425 Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five
426 years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young
427 adults. *PLoS Negl Trop Dis* 2018;12:e0006377. doi:10.1371/journal.pntd.0006377.
- 428 [16] Ivaniushina V, Radjef N, Alexeeva M, Gault E, Semenov S, Salhi M, et al. Hepatitis delta
429 virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. *J Gen Virol*
430 2001;82:2709–18. doi:10.1099/0022-1317-82-11-2709.
- 431 [17] Andernach IE, Leiss L V., Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, et al.
432 Characterization of hepatitis delta virus in sub-Saharan Africa. *J Clin Microbiol*
433 2014;52:1629–36. doi:10.1128/JCM.02297-13.

- 434 [18] Bekondi C, Olinger CM, Boua N, Talarmin A, Muller CP, Le Faou A, et al. Central African
435 Republic is part of the West-African hepatitis B virus genotype E crescent. *J Clin Virol*
436 2007;40:31–7. doi:10.1016/j.jcv.2007.05.009.
- 437 [19] Bekondi C. Aspects cliniques et epidemiologiques des infections a virus de l’hepatite b en
438 republique centrafricaine. Université Henri Poincaré - Nancy 1, 2007. doi:2008NAN10129.
- 439 [20] Bertoletti A, Hong M. Age-Dependent Immune Events during HBV Infection from Birth to
440 Adulthood: An Alternative Interpretation. *Front Immunol* 2014;5:441.
441 doi:10.3389/fimmu.2014.00441.
- 442 [21] Mora N, Adams WH, Kliethermes S, Dugas L, Balasubramanian N, Sandhu J, et al. A
443 Synthesis of Hepatitis C prevalence estimates in Sub-Saharan Africa: 2000-2013. *BMC*
444 *Infect Dis* 2016;16:1–8. doi:10.1186/s12879-016-1584-1.
- 445 [22] Lin CL KJ. The clinical implications of hepatitis B virus genotype: recent advances. *J*
446 *Gastroenterol Hepatol* 2011;26:123–130.
- 447 [23] *Toxoplasmosis of Animals and Man*. By J. P. Dubey and C. P. Beattie. 220 pages. ISBN 0
448 8493 4618 5. CRC Press, Boca Raton, 1988. £108.00. *Parasitology* 1990;100:500–1.
449 doi:10.1017/s0031182000078914.
- 450 [24] Koyaweda Giscard Wilfried, Rose J, Machuka E, Juma J, Macharia R, Patrice N, et al.
451 Detection of circulating hepatitis B virus immune escape and polymerase mutants among
452 HBV-positive patients attending Institut Pasteur de Bangui, Central African Republic. *Int J*
453 *Infect Dis* 2020;90:138–44. doi:10.1016/j.ijid.2019.10.039.
- 454 [25] Kramvis A. Genotypes and genetic Variability of Hepatitis B virus. *Intervirology*
455 2014;57:141–50. doi:10.1159/000360947.
- 456 [26] Forbi JC, Ben-Ayed Y, Xia GL, Vaughan G, Drobeniuc J, Switzer WM KY. Disparate
457 distribution of hepatitis B virus genotypes in four sub-Saharan African countries. *J Clin Virol*
458 2013;1:59–66. doi:doi: 10.1016/j.jcv.2013.06.028.
- 459 [27] Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth major clade

- 460 for hepatitis delta virus. *Emerg Infect Dis* 2006;12:1447–50. doi:10.3201/eid1209.060112.
- 461 [28] Brennan CA, Bodelle P, Coffey R, Devare SG, Golden A, Hackett J, et al. The Prevalence of
462 Diverse HIV-1 Strains Was Stable in Cameroonian Blood Donors From 1996 to 2004
463 2008;49:432–9.
- 464 [29] Ndembi N, Takehisa J, Zekeng L, Kobayashi E. Genetic Diversity of HIV Type 1 in Rural
465 Eastern Cameroon 2004;37:1641–50.
- 466 [30] Moussa S, Pinson P, Pelembi P, Gody J-C, Mbitikon O, Fikouma V, et al. First data on HIV-
467 1 resistance mutations to antiretroviral drugs in Central African Republic. *AIDS Res Hum*
468 *Retroviruses* 2010;26:1247–8. doi:10.1089/aid.2010.0091.
- 469 [31] Komas NP, Baï-Sepou S, Manirakiza A, Léal J, Béré A, Le Faou A. The prevalence of
470 hepatitis B virus markers in a cohort of students in Bangui, Central African Republic. *BMC*
471 *Infect Dis.* 2010;10:226. Published 2010 Jul 29. doi:10.1186/1471-2334-10-226.
- 472 [32] Njouom, R., Frost, E., Deslandes, S., Mamadou-Yaya, F., Labbe, A. C., Pouillot, R., ... &
473 Pepin, J. Predominance of hepatitis C virus genotype 4 infection and rapid transmission
474 between 1935 and 1965 in the Central African Republic. *Journal of general virology.* 2009;
475 90(10), 2452-2456.
- 476 [33] Njouom, R., Pasquier, C., Ayouba, A., Gessain, A., Froment, A., Mfoupouendoun, J., ... &
477 Nerrienet, E. High rate of hepatitis C virus infection and predominance of genotype 4 among
478 elderly inhabitants of a remote village of the rain forest of South Cameroon. *Journal of*
479 *medical virology.* 2003 ; 71(2), 219-225.

480
481
482




Figure 1

F





Figure 2



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.24.23294539>; this version posted August 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 3